X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

Content Team by Content Team
7th January 2022
in Market Moves, News
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe

Driven by the push from emerging as well as domestic markets in the upcoming quarters, the Indian Pharma industry in the Financial Year-22 is expected to be pegged at 9-11 percent, says credit rating agency, ICRA. ICRA’s sample of 21 Indian Pharma companies showed moderate growth of 6.4% in the second quarter of FY22, which diminished by 16% in the preceding quarter.

Some of the major reasons attributed to this cause hover around pricing pressures prevailing in the US market and the normalization of the base. That said, there remained healthy growth in the domestic and emerging markets. There was an increase of 15.3% year-on-year in the sample set recorded when it came to the domestic revenues as against a 14.6% year-on-year growth in the Indian Pharmaceutical Market. A steady normalization in the footfalls at hospitals along with field force operations had consistent traction in acute therapies, and better pricing supported healthy revenue growth across the companies.

As per ICRA, there will be sustenance as far as doctor visits and even elective surgeries go due to the rise of the Omicron variant. Besides that, the performance of new launches, apart from the momentum in the revenue growth, will continue to be a key analyzer. When it comes to the US market, the growth in the revenue for the sample set stood firmly muted at 1.9% in the second quarter because of high single-digit to low past erosion and also past inventory liquidation, highlighting COVID-related uncertainties that still exist.

Companies are now concentrating on specialty products, complex generics, injectables, etc., to enhance margins for the US business, which has already been impacted by pricing pressure. Notably, the companies in the sample set encountered a healthy growth y-o-y in revenue with an increase of just over 12 percent from the European business. This was essentially due to the improvement in the demand for non-COVID products and also new product introductions, Rupee depreciation, and of course, expanding market coverage.

Previous Post

Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of COVID-19 Vaccine in 2022

Next Post

WuXi STA's Shanghai Facility Gets FDA Nod Post Inspection

Related Posts

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
America Facing Heart Health Issues Since The Pandemic Began
News

America Facing Heart Health Issues Since The Pandemic Began

8th February 2022
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants
News

T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

7th February 2022
OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis
Manufacturing

Lilly announces $1 billion investment in new manufacturing facility in North Carolina

7th February 2022
Recipharm supports FDA approval of Perrigos AB-rated generic product
News

Recipharm acquires GenIbet to bolster Biologics offering

7th February 2022
Next Post
WuXi STA's Shanghai Facility Gets FDA Nod Post Inspection

WuXi STA's Shanghai Facility Gets FDA Nod Post Inspection

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In